Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 93% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, specifically Item 7.01 Regulation FD Disclosure. It is a regulatory filing with the SEC disclosing a ‘fireside chat’ presentation, not an earnings release, annual report, or any of the other specific categories. As an SEC Form 8-K with general regulatory information, it falls under Regulatory Filings (RNS).
2026-05-21 English
FORM 8-K
Capital/Financing Update Classification · 94% confidence The document is a Form 8-K (“Current Report pursuant to Section 13 or 15(d)”) describing the entry into a Securities Purchase Agreement and related Placement Agency and Lock-Up Agreements, detailing the sale of common stock and warrants and net proceeds of approximately $2 million. It is clearly a financing activity/registered direct offering. Under the classification scheme, this is a capital/financing update.
2026-05-20 English
424B5
Capital/Financing Update Classification · 84% confidence The document is a SEC Rule 424(b)(5) prospectus supplement describing a registered direct offering of common stock and warrants, clearly a primary fundraising/financing document detailing new share issuance and capital raising terms. This falls under Capital/Financing Update, rather than an earnings release or annual report.
2026-05-18 English
10-Q
Interim / Quarterly Report Q3 2026
2026-05-14 English
10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)
Interim / Quarterly Report Q2 2026
2026-02-17 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares and warrants by a selling stockholder. It details the offering of common stock underlying warrants, the use of proceeds, risk factors, and company business overview. It is a registration and offering document for securities, not a financial report, earnings release, or management discussion. The document is a capital/financing update describing a securities offering and related capital raising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement, but a full prospectus related to financing.
2025-12-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.